These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 9366427

  • 21. 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors.
    Guinn BA, Bertram EM, DeBenedette MA, Berinstein NL, Watts TH.
    Cell Immunol; 2001 May 25; 210(1):56-65. PubMed ID: 11485353
    [Abstract] [Full Text] [Related]

  • 22. Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization.
    Mendoza RB, Cantwell MJ, Kipps TJ.
    J Immunol; 1997 Dec 15; 159(12):5777-81. PubMed ID: 9550372
    [Abstract] [Full Text] [Related]

  • 23. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
    Bristol JA, Orsini C, Lindinger P, Thalhamer J, Abrams SI.
    Cell Immunol; 2000 Nov 01; 205(2):73-83. PubMed ID: 11104579
    [Abstract] [Full Text] [Related]

  • 24. Co-immunisation with DNA encoding RANK/RANKL or 4-1BBL costimulatory molecules does not enhance effector or memory CTL responses afforded by immunisation with a tumour antigen-encoding DNA vaccine.
    Herd KA, Wiethe C, Tindle RW.
    Vaccine; 2007 Jul 09; 25(28):5209-19. PubMed ID: 17544551
    [Abstract] [Full Text] [Related]

  • 25. Immune response enhancement by in vivo administration of B7.2Ig, a soluble costimulatory protein.
    Swiniarski H, Sturmhoefel K, Lee K, Gray GS, Thomas JL, Wolf SF, Dorner AJ, O'Toole M.
    Clin Immunol; 1999 Sep 09; 92(3):235-45. PubMed ID: 10479528
    [Abstract] [Full Text] [Related]

  • 26. Functional equivalency of B7-1 and B7-2 for costimulating plasmid DNA vaccine-elicited CTL responses.
    Santra S, Barouch DH, Jackson SS, Kuroda MJ, Schmitz JE, Lifton MA, Sharpe AH, Letvin NL.
    J Immunol; 2000 Dec 15; 165(12):6791-5. PubMed ID: 11120800
    [Abstract] [Full Text] [Related]

  • 27. B7-negative versus B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes.
    Yang G, Mizuno MT, Hellström KE, Chen L.
    J Immunol; 1997 Jan 15; 158(2):851-8. PubMed ID: 8993003
    [Abstract] [Full Text] [Related]

  • 28. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production.
    Schweitzer AN, Sharpe AH.
    J Immunol; 1998 Sep 15; 161(6):2762-71. PubMed ID: 9743334
    [Abstract] [Full Text] [Related]

  • 29. In vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins.
    Breloer M, Fleischer B, von Bonin A.
    J Immunol; 1999 Mar 15; 162(6):3141-7. PubMed ID: 10092763
    [Abstract] [Full Text] [Related]

  • 30. Human fibroblasts transduced with CD80 or CD86 efficiently trans-costimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity.
    Smythe JA, Fink PD, Logan GJ, Lees J, Rowe PB, Alexander IE.
    J Immunol; 1999 Sep 15; 163(6):3239-49. PubMed ID: 10477593
    [Abstract] [Full Text] [Related]

  • 31. B7.2-Ig fusion proteins enhance IL-4-dependent differentiation of tumor-sensitized CD8+ cytotoxic T lymphocyte precursors.
    Hiraoka S, Takeuchi N, Bian Y, Nakahara H, Kogo M, Dunussi-Joannopoulos K, Wolf S, Ono S, Fujiwara H.
    Int Immunol; 2005 Aug 15; 17(8):1071-9. PubMed ID: 16027141
    [Abstract] [Full Text] [Related]

  • 32. Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC.
    Schoenberger SP, Jonges LE, Mooijaart RJ, Hartgers F, Toes RE, Kast WM, Melief CJ, Offringa R.
    Cancer Res; 1998 Jul 15; 58(14):3094-100. PubMed ID: 9679976
    [Abstract] [Full Text] [Related]

  • 33. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.
    La Motte RN, Sharpe AH, Bluestone JA, Mokyr MB.
    J Immunol; 1999 Apr 15; 162(8):4817-23. PubMed ID: 10202025
    [Abstract] [Full Text] [Related]

  • 34. Prolonged survival of thymoma-bearing mice after vaccination with a soluble protein antigen entrapped in liposomes: a model study.
    Zhou F, Rouse BT, Huang L.
    Cancer Res; 1992 Nov 15; 52(22):6287-91. PubMed ID: 1384958
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes.
    Kim JJ, Bagarazzi ML, Trivedi N, Hu Y, Kazahaya K, Wilson DM, Ciccarelli R, Chattergoon MA, Dang K, Mahalingam S, Chalian AA, Agadjanyan MG, Boyer JD, Wang B, Weiner DB.
    Nat Biotechnol; 1997 Jul 15; 15(7):641-6. PubMed ID: 9219266
    [Abstract] [Full Text] [Related]

  • 37. Protection against a lethal challenge with SV40-transformed cells by the direct injection of DNA-encoding SV40 large tumor antigen.
    Bright RK, Beames B, Shearer MH, Kennedy RC.
    Cancer Res; 1996 Mar 01; 56(5):1126-30. PubMed ID: 8640771
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes.
    Johnston JV, Malacko AR, Mizuno MT, McGowan P, Hellström I, Hellström KE, Marquardt H, Chen L.
    J Exp Med; 1996 Mar 01; 183(3):791-800. PubMed ID: 8642283
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.